Navigation Links
Cell Therapeutics, Inc. Announces Closing of Registered Offering of $30 Million of Preferred Stock and Warrants
Date:8/21/2009

SEATTLE, Aug. 21 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (Nasdaq and MTA: CTIC) (the "Company") today announced the closing of its previously announced sale of $30 million of shares of its Series 2 Preferred Stock and warrants to purchase shares of its common stock in a registered offering to a single institutional investor. The investor has elected to convert all of its shares of Series 2 Preferred Stock and to receive the 18,853,103 shares of the Company's common stock issuable upon such conversion at the closing.

The Company received approximately $28.2 million in net proceeds from the offering, after deducting placement agent fees and estimated offering expenses.

In connection with the offering, the investor received warrants to purchase up to 4,713,276 shares of common stock. The warrants have an exercise price of $1.70 per warrant share, for total potential additional proceeds to the Company of approximately $8.0 million upon exercise of the warrants. The warrants are exercisable immediately upon their date of issuance and will expire nine months thereafter.

Rodman & Renshaw, LLC, a wholly-owned subsidiary of Rodman & Renshaw Capital Group, Inc. (Nasdaq: RODM), acted as the exclusive placement agent for the offering.

A shelf registration statement relating to the shares of Series 2 Preferred Stock and warrants issued in the offering (and the shares of common stock issuable upon conversion of the Series 2 Preferred Stock and exercise of the warrants) has been filed with the Securities and Exchange Commission (the "SEC"). The shelf registration statement was automatically effective upon filing with the SEC. A prospectus supplement relating to the offering has also been filed with the SEC. Copies of the
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Cell Therapeutics, Inc. Announces Institutional Investor Purchases $30 Million of Preferred Stock and Warrants
2. Oxygen Biotherapeutics, Inc. Files 10-K for Fiscal Year Ended April 30, 2009
3. Nile Therapeutics, Inc. Announces Dosing of First Patient in Phase 2 Study of CD-NP for the Treatment of Acute Heart Failure
4. Cell Therapeutics, Inc. Announces Exercise of Overallotment
5. Cell Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock and Warrants
6. Nile Therapeutics, Inc. Completes $3.4 Million Private Placement
7. Oxygen Biotherapeutics, Inc. Announces Closing of Private Placement Financing Agreement
8. Nile Therapeutics, Inc. To Raise $3.4 Million in Private Placement
9. Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions
10. Intarcia Therapeutics, Inc. Announces Acceptance of ITCA 650 Phase 1b Study for Late-Breaker Presentation at the American Diabetes Association 69th Scientific Sessions
11. Prospect Therapeutics, Inc.s GCS-100 Inhibited Blood Vessel Formation in a Variety of Cancer Models
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Based on the revenues gained from surgical imaging ... by four major players contributing to approximately 74% ... GE Healthcare (U.K.), Siemens AG (Germany), Philips (Netherlands), ... Copy at http://www.marketsandmarkets.com/Market-Reports/surgical-imaging-market-210534462.html , The leading ... its strong product portfolio, which includes its flagship ...
(Date:12/17/2014)... 17, 2014 Once more, EMAAR ... larger packaged waste water treatment plant to phase one ... City (KAEC). Two years ago Bioshaft successfully supplied and ... serving two residential towers with an occupancy of 900 ... quarter million gallons per day and was signed on ...
(Date:12/17/2014)... December 17, 2014 Audacity, a leading ... and member of the Huntsworth Health Group, is proud ... executive team. In her role, Gonzales will serve as ... are incredibly honored to welcome a talent of Jamie’s ... CEO, Gaëtan Fraikin. “She is a proven healthcare innovation ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
Breaking Biology Technology:Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 2Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 3Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 4Audacity Welcomes Healthcare Communications Expert Jamie Gonzales as Senior Vice President of Client Services 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4
... VRNM ), a leading developer of cellulosic ethanol,technology ... announced today that Carlos A. Riva, President and Chief ... and Company Clean,Energy Conference. The presentation is scheduled to ... and will take place at Le Parker Meridien in,New ...
... Life Sciences,Holdings, Inc. (Nasdaq: ADLS ) today ... present at the 2007 UBS Global Life Sciences,Conference ... New York on Wednesday,September 26 at 1:30 p.m. ... live webcast of the presentation will be accessible ...
... webcast Thursday, September 6, 2007, SAN DIEGO, ... ) announced today that Neurocrine Biosciences will,present at ... live presentation takes place Thursday, September 6, 2007 ... Time (PT). The presentation will be,simultaneously webcast and ...
Cached Biology Technology:Verenium Corporation to Present at the Upcoming Cowen and Company Clean Energy Conference 2Verenium Corporation to Present at the Upcoming Cowen and Company Clean Energy Conference 3Advanced Life Sciences to Present at 2007 UBS Global Life Sciences Conference 2
(Date:12/17/2014)... 15, 2014  HITLAB SM announced today ... audit to confirm its adherence to current U.S. ... enables HITLAB to conduct regulated smart device and ... for patient safety and research quality. ... quality, and delivery with innovative technology," said ...
(Date:12/17/2014)... DUBLIN , Dec. 16, 2014 Research ... announced the addition of the "Global Chemical ... http://photos.prnewswire.com/prnh/20130307/600769 ... is the increasing demand for medical sensors in ... patient data for quick and correct diagnosis during ...
(Date:12/15/2014)... DUBLIN , Dec. 12, 2014 Research ... announced the addition of the "Global Facial ... http://photos.prnewswire.com/prnh/20130307/600769 ... the identification of individuals. Facial recognition system measures ... as nose, jaw edges, mouth, and the distance ...
Breaking Biology News(10 mins):HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
... medical woes ranging from cancer to bird flu will ... The newly-patented device will offer small and medium-sized researchers ... It will also allow them a chance, at last, ... analyze drugs and view the characteristics of protein. ...
... a gene known to increase the risk of Alzheimer,s ... Oregon Health & Science University study has found. ... that 7- to 10-year-olds with a member of a ... and neuroprotection display reduced spatial learning and memory, associated ...
... include: continental deformation and the San Andreas fault; ... between Britain and America; environmental stress and the ... Canada,s Mackenzie River basin as a CO2 source ... the absence of active volcanism; and geologic evolution ...
Cached Biology News:Council to honor NJIT SmartPin 2Children with gene show reduced cognitive function 2November GEOLOGY and GSA TODAY Media Highlights 2November GEOLOGY and GSA TODAY Media Highlights 3November GEOLOGY and GSA TODAY Media Highlights 4November GEOLOGY and GSA TODAY Media Highlights 5November GEOLOGY and GSA TODAY Media Highlights 6November GEOLOGY and GSA TODAY Media Highlights 7November GEOLOGY and GSA TODAY Media Highlights 8November GEOLOGY and GSA TODAY Media Highlights 9November GEOLOGY and GSA TODAY Media Highlights 10
... Opticon real-time PCR detection system uses a ... (450-495 nm) and a photomultiplier tube for ... is built on an DNA Engine thermal ... feature. This item includes the thermal cycler, ...
... MyiQ detection system is used for single-color ... VIC, TET, or JOE fluorophores and features ... of fluorescence data from 96 wells, a ... customizable end-point analysis. The system includes the ...
... Microdissection , CapSure HS and CapSure Macro ... extraction of populations of pure cells from ... Capture Microdissection., Ensure the Integrity of ... All CapSure LCM Caps have a patented ...
... The new MyiQ real-time PCR detection system ... of common green fluorescent dyes such as ... interfaces directly with the iCycler thermal cycler, ... and Peltier-effect driven performance. The MyiQ real-time ...
Biology Products: